EXAGEN INC. (XGN) News

EXAGEN INC. (XGN): $5.74

0.13 (+2.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter XGN News Items

XGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XGN News Highlights

  • For XGN, its 30 day story count is now at 2.
  • Over the past 6 days, the trend for XGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about XGN are GAN.

Latest XGN News From Around the Web

Below are the latest news stories about Exagen Inc that investors may wish to consider to help them evaluate XGN as an investment opportunity.

Samjo Capital LLC Buys RumbleON Inc, Iteris Inc, Thryv Holdings Inc, Sells GAN, Exagen Inc, ...

Investment company Samjo Capital LLC (Current Portfolio) buys RumbleON Inc, Iteris Inc, Thryv Holdings Inc, Research Solutions Inc, sells GAN, Exagen Inc, Quotient Technology Inc, Nephros Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Samjo Capital LLC.

Yahoo | February 8, 2022

Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022. Ron Rocca, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, February 16 at 2:00 PM ET, which is accessible to con

Yahoo | February 2, 2022

Health Check: How Prudently Does Exagen (NASDAQ:XGN) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | January 12, 2022

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ: XGN ), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement. The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients. Both parties will contribute to the development of the patent-pending assays, leading to the commercialization of novel molecular assays that segment patients according to gene expression in their synovial tissue biopsies. RA is estimated to affect approximately two million patients in the United States and be twi...

Benzinga | January 9, 2022

Cowen Prime Advisors LLC Invests $2.49 Million in Exagen Inc. (NASDAQ:XGN)

Cowen Prime Advisors LLC acquired a new position in shares of Exagen Inc. (NASDAQ:XGN) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 182,900 shares of the companys stock, valued at approximately $2,487,000. Cowen Prime Advisors LLC owned approximately 1.13% of Exagen as of its most recent []

Dakota Financial News | December 23, 2021

$11.80 Million in Sales Expected for Exagen Inc. (NASDAQ:XGN) This Quarter

Analysts expect Exagen Inc. (NASDAQ:XGN) to announce sales of $11.80 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Exagens earnings. The lowest sales estimate is $11.30 million and the highest is $12.30 million. Exagen reported sales of $12.67 million during the same quarter last year, which indicates []

Dakota Financial News | December 17, 2021

-$0.50 EPS Expected for Exagen Inc. (NASDAQ:XGN) This Quarter

Equities research analysts expect Exagen Inc. (NASDAQ:XGN) to announce ($0.50) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Exagen’s earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.50). Exagen posted earnings of ($0.27) per share in the same quarter […]

Dakota Financial News | December 15, 2021

Morgan Stanley Purchases 266,001 Shares of Exagen Inc. (NASDAQ:XGN)

Morgan Stanley lifted its position in Exagen Inc. (NASDAQ:XGN) by 269.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 364,864 shares of the companys stock after buying an additional 266,001 shares during the period. Morgan Stanleys holdings in Exagen were worth []

Transcript Daily | December 7, 2021

Exagen Inc. (NASDAQ:XGN) Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System lifted its holdings in Exagen Inc. (NASDAQ:XGN) by 105.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,849 shares of the companys stock after purchasing an additional 7,630 shares during the period. California State Teachers Retirement System []

Transcript Daily | December 4, 2021

Charles Schwab Investment Management Inc. Has $406,000 Holdings in Exagen Inc. (NASDAQ:XGN)

Charles Schwab Investment Management Inc. raised its holdings in shares of Exagen Inc. (NASDAQ:XGN) by 164.1% during the second quarter, HoldingsChannel.com reports. The firm owned 27,074 shares of the companys stock after acquiring an additional 16,821 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Exagen were worth $406,000 at the end of []

Dakota Financial News | December 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5164 seconds.